Subjective and Objective Effects of the Novel Triple Reuptake Inhibitor Tesofensine in Recreational Stimulant Users

@article{Schoedel2010SubjectiveAO,
  title={Subjective and Objective Effects of the Novel Triple Reuptake Inhibitor Tesofensine in Recreational Stimulant Users},
  author={Kerri A. Schoedel and Dieter H. Meier and Bijan Chakraborty and P. M. Manniche and Edward Sellers},
  journal={Clinical Pharmacology \& Therapeutics},
  year={2010},
  volume={88}
}
Tesofensine is a (triple) reuptake inhibitor of noradrenaline, dopamine, and serotonin that is in development for the treatment of obesity. The abuse potential of triple reuptake inhibitors is not yet known, and so this study was undertaken to evaluate the potential abuse‐related effects of tesofensine in humans. It was designed as a single‐dose, randomized, double‐blind, crossover study involving tesofensine vs. placebo, D‐amphetamine (positive control for dopaminergic/stimulant effects… 
Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study
TLDR
The overall incidence of abuse-related adverse events, such as euphoric mood and hallucination, was numerically lower with suvorexant than zolpidem, suggesting that the overall abuse liability of suvorxant may be lower than zOLpidem.
Human Abuse Potential and Cognitive Effects of Taranabant, a Cannabinoid 1 Receptor Inverse Agonist: A Randomized, Double-Blind, Placebo- and Active-Controlled, Crossover Study in Recreational Polydrug Users
TLDR
Taranabant did not consistently show stimulant/cannabis-like effects or abuse potential in recreational polydrug users, indicating that cannabinoid 1 receptor inverse agonists/antagonists are unlikely to be recreationally abused.
Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity
TLDR
The enhancement of serotonin, NE, and DA in rat brain regions associated with depression suggest that amitifadine may have novel antidepressant activity.
Serotonergic Anti-Obesity Agents
TLDR
Evidence indicates that tesofensine strengthens satiety, but behavioural specificity and psychological side effects remain an issue, and the serotonergic system remains a viable target for anti-obesity treatment.
A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor
TLDR
Solriamfetol appears to have abuse potential similar to or lower than phentermine, and ratings of negative subjective effects were higher with solriam Fetol 600 and 1200 mg relative to Phentermine.
...
...

References

SHOWING 1-10 OF 56 REFERENCES
Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines.
TLDR
This short-term, single-dose study provides strong evidence that sibutramine does not have the potential for abuse that is characteristic of amphetamines and that it is indistinguishable from placebo in abuse potential.
Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease
TLDR
It is possible that inhibition of dopamine reuptake alone does not provide clinical benefit in early Parkinson's disease, adequate inhibition of serotonin and norepinephrine was not achieved in this study, or countervailing physiologic mechanisms offset the potential benefit.
Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study.
TLDR
Patients with PD in advanced stages showed modest improvements in UPDRS subscale II plus subscale III total score and in off time when treated with tesofensine, but a dose-response relationship could not be established for efficacy, while adverse drug reactions tended to be more frequent at higher dosages.
Comparison of the effects of sibutramine and other weight‐modifying drugs on extracellular dopamine in the nucleus accumbens of freely moving rats
TLDR
It is suggested that dopaminergic reward mechanisms are not involved in the reduction of food intake by sibutramine, and this finding is consistent with the view that sibUTramine lacks abuse potential.
Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans
TLDR
Both methylphenidate and d-amphetamine produced dose-dependent increases in stimulant-like subject ratings (e.g. Active, Alert, or Energetic and High), but the effects of these drugs were not isomorphic.
Assessment of Pharmacokinetics and Pharmacodynamic Effects Related to Abuse Potential of a Unique Oral Osmotic‐Controlled Extended‐Release Methylphenidate Formulation in Humans
TLDR
The hypothesis that a formulation can modulate abuse potential by controlling the rate and extent of drug delivery is supported.
Do Formulation Differences Alter Abuse Liability of Methylphenidate?: A Placebo-Controlled, Randomized, Double-Blind, Crossover Study in Recreational Drug Users
TLDR
The results suggest that OROS methylphenidate, with its characteristic slow ascending plasma concentration profile, may have lower abuse potential, reflected by lower subjective responses during early hours as compared with the IR formulation with its rapid drug delivery and accompanying greater subjective effects.
Human Abuse Liability of the Smoking Cessation Drug Varenicline in Smokers and Nonsmokers
TLDR
It is concluded that varenicline is unlikely to be abused, and the overall patterns were similar, with the exception that thenonsmokers group showed some small positive effects balanced by some negative effects when compared with the effects of placebo.
Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans
TLDR
Empirical evidence is provided for the commonly accepted belief that the abuse liability of cocaine can be enhanced by increasing the rate of the intravenous infusion; this principal may not hold true for opioids but further work would be required to rule this out.
...
...